卡维地洛对慢性心衰患者糖、脂代谢的影响

Effects of Carvedilol on Glucose and Lipid Metablism in Patients with Chronic Heart Failure

目的观察卡维地洛对慢性心衰患者的疗效及其对血糖,血脂代谢的影响。方法入选CHF患者59例,随机分为对照组:应用常规抗CHF治疗组(30例)和卡维地洛组(29例),后者在常规抗CHF治疗基础上加用卡维地洛,疗程为24周,治疗前后均测定左室舒张末期内径(LVDd)和收缩末期内径(LVDs)、左室射血分数(LVEF)、空腹血糖(FBS)、糖化血红蛋白(HbAlc)、血脂。结果卡维地洛组改善LVDd、LVDs和LVEF均优于常规抗CHF治疗组(P<0.01),治疗后卡维地络组TC、LDL-C较对照组降低(P<0.05)。结论卡维地洛可有效改善CHF患者的心功能,对糖、脂代谢有一定的益处。

Objective To investigate the effects of carvedilol on glucose and lipid metabolism in patients with chronic heart failure （CHF）. Methods Fifty nine patients with CHF were divided randomly into CHF treatment group （30 cases） and carvedilol treatment group （29 cases）. LVDd, LVDs, LVEF, FBS, HbAIc, TC, TG, LDL-C and HDL-C were detected before and after 24 week＇ s treatment. Results Compared with CHF treatment group, LVEF was significantly increased （39.6 ±4.5 % Vs 36.3±5.0 %, P 〈 0.01 ）, and LVDd, LVDs were significantly decreased in carvedilol treatment group （55.2 ± 5.9 Vs 62.6 ± 5.7, 45.6 ± 6.4 Vs 53.2 ± 5.6, respectively; P 〈 0.01 ）. TC, LDL - C in carvedilol treatment group were significantly decreased （5.22 ± 0.6 Vs 5.88 ± 0.89; 3.4 ± 0.8 Vs 4.0 ± 0.9; P 〈 0.05）. Conclusions Carvedilol could improve cardiac function and had benefit for glucose and lipid metabolism.